MedTrace Logo

Dipeptidyl Peptidase-4 Inhibition and Immune Function in HIV

NCT01093651 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2014-02-17

Study results available
· View outcomes & findings →

Summary

We will test the safety of a new class of anti-diabetes compounds (DPPIV-inhibitors) in people living with HIV. Future trials will examine efficacy for treating diabetes and reducing cardiovascular disease risk in people living with HIV.

Conditions

Interventions

DRUG

Sitagliptin

100 mg sitagliptin daily for 4-6 months

DRUG

Placebo

Daily placebo for 4-6 months

Sponsors & Collaborators

  • The Campbell Foundation

    collaborator OTHER

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Kevin E Yarasheski, PhD · Washington University School of Medicine

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2011-06-30
Completion
2012-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01093651 on ClinicalTrials.gov